Other papers submitted by: Dr David Henderson

open access to scientific and medical research

News:

Expressions of interest for Editor-in-Chief - the International Medical Case Reports Journal Read more

Back to User profile » Dr David Henderson

Paper published by Dr David Henderson:

Original Research

Noteworthy comment: This paper is noteworthy because it describes a new tool to assess patients’ perspectives on a serious, often distressing aspect of a chronic mental illness—ie, cognitive impairment associated with schizophrenia. As recommended by the FDA’s guidance on patient-reported outcome (PRO) measures, the multistage development process utilized by the investigators incorporated quantitative and qualitative data from patients and providers. Given the importance to patients of receiving understandable information about their conditions, this new PRO measure may prove valuable in building a therapeutic alliance with patients with schizophrenia. Furthermore, following psychometric validation in an ongoing clinical trial, the measure could define key patient-oriented endpoints for future trials.

Highly-accessed

Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia

Welch LC, Trudeau JJ, Silverstein SM, Sand M, Henderson DC, Rosen RC

Patient Related Outcome Measures 2017, 8:71-81

Published Date: 8 June 2017